Your browser is no longer supported. Please, upgrade your browser.
AMRS [NASD]
Amyris, Inc.
Index- P/E- EPS (ttm)-1.87 Insider Own33.01% Shs Outstand227.27M Perf Week3.10%
Market Cap2.93B Forward P/E- EPS next Y-0.37 Insider Trans0.00% Shs Float154.20M Perf Month41.00%
Income-350.90M PEG- EPS next Q-0.09 Inst Own42.00% Short Float15.51% Perf Quarter545.37%
Sales133.90M P/S21.89 EPS this Y27.80% Inst Trans-5.89% Short Ratio4.89 Perf Half Y332.15%
Book/sh-0.39 P/B- EPS next Y72.90% ROA-179.60% Target Price12.00 Perf Year345.29%
Cash/sh0.19 P/C76.53 EPS next 5Y30.00% ROE242.80% 52W Range1.40 - 18.57 Perf YTD137.25%
Dividend- P/FCF- EPS past 5Y-51.90% ROI- 52W High-17.72% Beta1.05
Dividend %- Quick Ratio0.90 Sales past 5Y28.70% Gross Margin37.70% 52W Low991.43% ATR1.74
Employees561 Current Ratio1.30 Sales Q/Q-2.00% Oper. Margin- RSI (14)60.86 Volatility14.45% 12.95%
OptionableYes Debt/Eq- EPS Q/Q34.40% Profit Margin- Rel Volume0.49 Prev Close14.65
ShortableYes LT Debt/Eq- EarningsMar 02 BMO Payout- Avg Volume4.89M Price15.28
Recom1.50 SMA2019.13% SMA5062.44% SMA200210.84% Volume1,991,059 Change4.30%
Jan-06-21Upgrade Cowen Market Perform → Outperform $9
Nov-25-20Initiated Jefferies Buy $3.35
Nov-25-20Initiated Cowen Market Perform $5
Dec-12-19Initiated Oppenheimer Outperform $8
Nov-14-18Reiterated B. Riley FBR Buy $10 → $8
Jan-25-18Initiated B. Riley FBR, Inc. Buy $8
May-28-14Resumed Stifel Hold
Feb-10-12Downgrade Deutsche Bank Buy → Hold $20 → $9
Nov-02-11Downgrade Robert W. Baird Outperform → Neutral $25 → $16
Jan-28-11Downgrade Stifel Nicolaus Buy → Hold
Nov-08-10Initiated Stifel Nicolaus Buy $22
Feb-24-21 08:00AM  
Feb-22-21 08:00AM  
Feb-17-21 08:00AM  
Feb-10-21 08:00AM  
Feb-03-21 08:00AM  
Feb-02-21 08:00AM  
Jan-26-21 04:08PM  
Jan-22-21 10:50PM  
08:00AM  
Jan-21-21 04:23PM  
Jan-15-21 08:00AM  
Jan-11-21 08:00AM  
Jan-04-21 08:00AM  
Dec-28-20 08:00AM  
Dec-24-20 08:52AM  
Dec-21-20 09:30AM  
08:44AM  
08:00AM  
Dec-16-20 08:00AM  
Dec-11-20 10:34AM  
Dec-08-20 09:00AM  
Dec-03-20 08:00AM  
Nov-30-20 08:00AM  
Nov-23-20 08:00AM  
Nov-18-20 10:23AM  
Nov-05-20 08:00AM  
Oct-30-20 08:00AM  
Oct-26-20 11:00AM  
Oct-23-20 07:06PM  
08:00AM  
Oct-22-20 08:00AM  
Oct-20-20 09:30AM  
Oct-09-20 09:00AM  
Oct-08-20 09:00AM  
Oct-07-20 09:22AM  
Oct-01-20 08:30AM  
Sep-22-20 07:00PM  
Sep-21-20 08:30AM  
Sep-15-20 08:30AM  
Sep-14-20 07:00AM  
Sep-11-20 04:22PM  
03:25PM  
05:00AM  
Sep-10-20 03:41PM  
Sep-08-20 08:30AM  
Sep-04-20 08:50AM  
Sep-01-20 03:30PM  
08:30AM  
08:30AM  
Aug-20-20 08:31AM  
Aug-14-20 08:30AM  
Aug-06-20 08:30AM  
Jul-29-20 05:01PM  
12:25PM  
Jul-28-20 09:07PM  
Jul-27-20 12:41PM  
08:30AM  
Jul-23-20 08:30AM  
Jul-20-20 01:29PM  
01:20PM  
09:53AM  
Jul-18-20 11:16AM  
Jul-17-20 12:40PM  
Jul-16-20 07:25PM  
06:31PM  
Jul-15-20 03:40PM  
08:30AM  
Jul-09-20 10:00AM  
Jul-02-20 10:39PM  
Jun-30-20 08:30AM  
Jun-29-20 12:00PM  
Jun-22-20 08:30AM  
Jun-10-20 08:30AM  
Jun-04-20 08:58AM  
Jun-02-20 08:37AM  
Jun-01-20 05:31PM  
12:29PM  
12:00PM  
May-27-20 01:33PM  
May-21-20 09:18AM  
May-17-20 08:00PM  
May-15-20 08:30AM  
May-14-20 09:36AM  
08:30AM  
May-08-20 08:30AM  
May-07-20 08:30AM  
May-04-20 08:30AM  
Apr-21-20 07:10PM  
Apr-20-20 08:30AM  
Apr-13-20 07:30AM  
Mar-31-20 08:30AM  
Mar-26-20 08:30AM  
Mar-24-20 10:01PM  
Mar-23-20 06:13AM  
Mar-16-20 08:05AM  
Mar-12-20 04:15PM  
02:30PM  
Mar-10-20 08:30AM  
Mar-09-20 08:30AM  
Mar-06-20 08:30AM  
Amyris, Inc., a biotechnology company, develops technology that creates microbial strains to produce artemisinic acid, a precursor of artemisinin, an anti-malarial drug. The company's technology platform enables to engineer microbes and use them as catalysts to metabolize renewable, plant-sourced sugars into large volume, high-value ingredients. It applies technology platform to engineer, manufacture, and sell products for the clean health and beauty, and flavor and fragrance markets. The company operates under the Amyris, Biofene, Biossance, Pipette, Purecane, and No Compromise trademarks. Amyris, Inc. has a collaboration agreement with the Infectious Disease Research Institute to advance a novel ribonucleic acid vaccine platform, including accelerating the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was founded in 2003 and is headquartered in Emeryville, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DOERR L JOHNDirectorDec 11Option Exercise2.875,000,00014,350,00070,156,794Dec 15 07:18 PM
Kung FrankDirectorJun 05Buy3.003,689,22511,067,6756,284,876Jun 09 09:06 PM
DOERR L JOHNDirectorMar 11Option Exercise2.875,226,48115,000,00058,490,128Mar 13 08:26 PM